The mrna therapeutics market in the UAE is expected to reach a projected revenue of US$ 140.0 million by 2030. A compound annual growth rate of 12.5% is expected of the UAE mrna therapeutics market from 2024 to 2030.
The UAE mrna therapeutics market generated a revenue of USD 61.3 million in 2023 and is expected to reach USD 140.0 million by 2030.
The UAE market is expected to grow at a CAGR of 12.5% from 2024 to 2030.
In terms of segment, infectious diseases was the largest revenue generating application in 2023.
Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
Market revenue in 2023
USD 61.3 million
Market revenue in 2030
USD 140.0 million
Growth rate
12.5% (CAGR from 2023 to 2030)
Largest segment
Infectious diseases
Fastest growing segment
Infectious Diseases
Historical data
2021 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Infectious Diseases
Key market players worldwide
Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS
Other key industry trends
In terms of revenue, UAE accounted for 0.5% of the global mrna therapeutics market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Middle East & Africa, Saudi Arabia mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 140.0 million by 2030.
The UAE pharmaceuticals market is rapidly growing. Although the UAE currently imports the majority of its pharmaceuticals, this scenario is changing. Some international pharmaceutical giants have partnered with UAE companies to manufacture products locally.
The COVID-19 pandemic increased the country’s focus on investing in life sciences domestically and internationally. For instance, in January 2023, National Resilience planned to build the first Good Manufacturing Facility in the UAE to manufacture COVID-19 vaccine for Modern a, Inc. and plasma-derived products for Takeda Pharmaceuticals.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to MRNA Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 100.0% in 2023.
Horizon Databook has segmented the Uae mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The UAE pharmaceuticals market is rapidly growing. Although the UAE currently imports the majority of its pharmaceuticals, this scenario is changing. Some international pharmaceutical giants have partnered with UAE companies to manufacture products locally.
The COVID-19 pandemic increased the country’s focus on investing in life sciences domestically and internationally. For instance, in January 2023, National Resilience planned to build the first Good Manufacturing Facility in the UAE to manufacture COVID-19 vaccine for Modern a, Inc. and plasma-derived products for Takeda Pharmaceuticals.
Uae Mrna Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2030)
Infectious Diseases
Oncology
Rare Genetic Diseases
Respiratory Diseases
Others
Uae Mrna Therapeutics Market Type Outlook (Revenue, USD Million , 2021-2030)
Prophylactic
Therapeutic
Uae Mrna Therapeutics Market End Use Outlook (Revenue, USD Million , 2021-2030)
Hospitals & Clinics
Research Organizations
Others
Reasons to subscribe to MRNA Therapeutics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of MRNA Therapeutics Market Outlook databook
Our clientele includes a mix of MRNA Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE MRNA Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into UAE MRNA Therapeutics Market Outlook from 2021 to 2030, including revenue numbers, major trends, and company profiles.